Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 3, 2012, Pages 529-536

  Fridley, Brooke L ^a   Jenkins, Gregory D ^a   Tsai, Ya Yu ^b   Song, Honglin ^c   Bolton, Kelly L ^d   Fenstermacher, David ^b   Tyrer, Jonathan ^c   Ramus, Susan J ^f   Cunningham, Julie M ^a   Vierkant, Robert A ^a   Chen, Zhihua ^b   Chen, Y Ann ^b   Iversen, Ed ^g   Menon, Usha ⁱ   Gentry Maharaj, Aleksandra ⁱ   Schildkraut, Joellen ^h   Sutphen, Rebecca ^e   Gayther, Simon A ^f   Hartmann, Lynn C ^a   Pharoah, Paul D P ^c   Sellers, Thomas A ^b   Goode, Ellen L ^a   more..

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Department of Oncology ^*  (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g DUKE UNIVERSITY   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ARTICLE; BINDING SITE; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; EPITHELIAL OVARIAN CANCER; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HISTOLOGY; HUMAN; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MEIOSIS; MISMATCH REPAIR; OVARY CANCER; OVERALL SURVIVAL; PHARMACOGENOMICS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE SUSCEPTIBILITY; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84859378506     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0741     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, Jacques S, Malone J, Munkarah AR. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120-7. (Pubitemid 37373908)
3. McGuire V, Jesser CA, Whittemore AS. Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399-403. (Pubitemid 34211865)
4. Hoskins PJ, O'Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN, Benedet JL. Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol 1992;10:1561-8. (Pubitemid 23057985)
5. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, et al. Inherited determinants of ovarian cancer survival. Clin Cancer Res 2010;16:995-1007.
6. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008;14:5594-601.
7. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 2008;26:3598-606.
8. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010;42:880-4.
9. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev 2001;2:91-9. (Pubitemid 33674000)
10. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. Nat Rev 2005;6:95-108. (Pubitemid 40179532)
11. Wang WY, Barratt BJ, Clayton DG, Todd JA. Genome-wide association studies: theoretical and practical concerns. Nat Rev 2005;6:109-18. (Pubitemid 40179533)
12. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008;40:695-701. (Pubitemid 351748875)
13. Menashe I, Maeder D, Garcia-Closas M, Figueroa JD, Bhattacharjee S, Rotunno M, et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res 2010;70:4453-9.
14. Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 2008;92:265-72.
15. Fridley BL, Biernacka JM. Gene set analysis of SNP data: benefits, challenges, and future directions. Eur J Hum Genet 2011;19:837-43.
16. Wang K, Li M, Hakonarson H. Analysing biological pathways in genome-wide association studies. Nat Rev Genet 2010;11:843-54.
17. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am J Hum Genet 2010;86:6-22.
18. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007;31:383-95. (Pubitemid 47051001)
19. Zaykin DV, Zhivotovsky LA, Czika W, Shao S, Wolfinger RD. Combining p-values in large-scale genomics experiments. Pharm Stat 2007;6:217-26. (Pubitemid 47455261)
20. Biernacka JM, Jenkins GD, Wang Y, Moyer AM, Fridley BL. Use of the gamma method for self-contained gene set analysis of SNP data. Eur J Hum Genet. 2011 Dec 14. [Epub ahead of print].
21. Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, et al. Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2011;20:1131-45.
22. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009;41:996-1000.
23. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000;155:945-59. (Pubitemid 30397141)
24. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9. (Pubitemid 30257031)
25. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30. (Pubitemid 30047706)
26. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001;1:167-70. (Pubitemid 33756654)
27. Fisher RA. Statistical methods for research workers. London, UK: Oliver and Boyd; 1932.
28. Jolliffe IT. Principal components analysis. 2nd ed. New York: Springer-Verlag; 2002.
29. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B Methodol 1972;34:187-220.
30. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
31. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904-9. (Pubitemid 44141658)
32. Chai HS, Sicotte H, Bailey KR, Turner ST, Asmann YW, Kocher JP. GLOSSI: a method to assess the association of genetic loci-sets with complex diseases. BMC Bioinformatics 2009;10:102.
33. De la Cruz O, Wen X, Ke B, Song M, Nicolae DL. Gene, region and pathway level analyses in whole-genome studies. Genet Epidemiol 2010;34:222-31.
34. Gene Ontology Project. Gene set intracellular signaling pathway. Available from: http://www.ebi.ac.uk/QuickGO/GTerm?id=GO:0023034. 5/4/2011.
35. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
36. Gene Ontology Project. Gene set FK506 binding. Available from: http://gowiki.tamu.edu/wiki/index.php/Category:GO:0005528-!-FK506-binding. 5/4/2011
37. Henriksen R, Sorensen FB, Orntoft TF, Birkenkamp-Demtroder K. Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium. Tumour Biol 2011;32:671-6.